Stereotactic Ablative Radiotherapy (SABR) in inoperable oligometastatic disease from colorectal cancer: A safe and effective approach

Tiziana Comito, Luca Cozzi, Elena Clerici, Maria C. Campisi, Rocco Luca E Liardo, Pierina Navarria, AnnaMaria Ascolese, Angelo Tozzi, Cristina Iftode, Fiorenza De Rose, Elisa Villa, Nicola Personeni, Lorenza Rimassa, Armando Santoro, Antonella Fogliata, Pietro Mancosu, Stefano Tomatis, Marta Scorsetti

Research output: Contribution to journalArticlepeer-review


Background: To assess the safety and efficacy of Stereotactic Ablative Radiotherapy (SABR) in oligometastatic patients from colorectal cancer.Methods: 82 patients with 1-3 inoperable metastases confined to one organ (liver or lung), were treated with SABR for a total of 112 lesions in an observational study. Prescription dose ranged between 48 and 75Gy in 3 or 4 consecutive fractions. Primary end-points were local control (LC), overall survival (OS) and progression-free survival (PFS). Secondary end-point was toxicity.Results: Median follow-up was 24 months (range 3-47). One, two and three years LC rate was 90%,80% and 75% (85%,75% and 70% for lung and 95%, 90% and 85% for liver metastases; no statistically significance was found). The difference in LC between the subgroup of lesions treated with ≥60 Gy (n = 58) and those irradiated with <60 Gy (n = 52) was statistically significant, with a 1, 2 and 3 yrs LC of 97%,92% and 83% for the higher dose, compared to 85%,70% and 70% for the lower dose (p < 0.04). Median OS was 32 months. Actuarial OS rate at 1, 2 and 3 yrs was 85%,65% and 43%. Univariate analysis showed a correlation only between OS and cumulative GTV > 3 cm (p < 0.02). Median PFS was 14 months, with a PFS rate of 56% at 1 yr and 40% at 2-3 yrs, without correlation with the site and prescription dose (p < 0.48 and p < 0.56). No patients experienced radiation-induced liver disease or grade >3 toxicity.Conclusions: SABR is a safe and feasible alternative treatment of oligometastatic colorectal liver and lung metastases in patients not amenable to surgery or other ablative treatments.

Original languageEnglish
Article number619
JournalBMC Cancer
Issue number1
Publication statusPublished - Jul 27 2014


  • Colorectal oligometastases
  • Liver
  • Lung
  • RapidArc
  • Stereotactic ablative radiotherapy

ASJC Scopus subject areas

  • Oncology
  • Cancer Research
  • Genetics
  • Medicine(all)


Dive into the research topics of 'Stereotactic Ablative Radiotherapy (SABR) in inoperable oligometastatic disease from colorectal cancer: A safe and effective approach'. Together they form a unique fingerprint.

Cite this